Ashwagandha and Hormonal Balance: How KSM-66 Reduces Cortisol, Modulates DHEA-S, and Supports Testosterone

Table of Contents

1. Direct Answer
2. TL;DR
3. The Study: Design and What Was Measured
4. Cortisol: The HPA Axis Mechanism
5. DHEA-S: What the Reduction Actually Means
6. Testosterone: What the Data Shows for Male Athletes
7. Why This Matters for Hybrid Athletes
8. Dosing, Timing, and Safety
9. Frequently Asked Questions
10. Conclusion

Hybrid athletes training 8–12 hours per week face a cortisol problem that most recovery protocols ignore. Prolonged endurance work, high-intensity strength sessions, inadequate sleep, and occupational stress all activate the hypothalamic-pituitary-adrenal (HPA) axis, producing cortisol elevation that persists for hours post-session and, in chronically overtrained athletes, remains elevated baseline. The downstream effects — suppressed testosterone, impaired muscle protein synthesis, disrupted sleep, degraded training quality — accumulate quietly until performance plateaus or drops. Ashwagandha, specifically the standardized KSM-66 root extract at 600 mg/day, is the most evidence-supported single intervention for managing this hormonal dynamic. This article examines what the controlled trial data actually shows.

Direct Answer

TL;DR

Ashwagandha (KSM-66, 600 mg/day) is an adaptogen that modulates the HPA axis — reducing chronic cortisol burden rather than eliminating the acute stress response entirely. A 60-day RCT at 240 mg/day showed 23% cortisol reduction, 8% DHEA-S reduction (reflecting overall adrenal stress output downregulation), and 11% testosterone increase in men. The testosterone increase results from reduced cortisol steal: when cortisol demand on shared steroidogenic precursors decreases, the HPG axis (hypothalamic-pituitary-gonadal) resumes more normal testosterone synthesis. For hybrid athletes, this hormonal shift matters because the testosterone-to-cortisol (T:C) ratio is the primary determinant of whether a training week's stress drives hypertrophic adaptation or muscle protein catabolism. Fathom Hydrate+ delivers KSM-66 at 600 mg per serving — twice the dose used in the study above, consistent with the higher-dose protocols showing the largest magnitude of effect in the literature. It is taken post-session, precisely when the cortisol burden from training is highest and the T:C ratio is at its most unfavorable.

The Study: Design and What Was Measured

Overview

Researchers enrolled 60 healthy adults aged 18–65 with mild stress (Hamilton Anxiety Rating Scale confirmed) in a 60-day randomized, double-blind, placebo-controlled trial. Participants received either 240 mg/day of standardized ashwagandha root extract (Shoden, standardized to ≥35% withanolide glycosides — delivering 84 mg of active compounds daily) or matched placebo. Blood samples collected in the morning — when cortisol normally peaks — assessed serum cortisol, DHEA-S, and testosterone at baseline, day 30, and day 60. All 60 participants completed the full trial with zero dropouts and zero adverse events; compliance exceeded 90%.

Key study outcomes

Cortisol: The HPA Axis Mechanism

How the HPA axis works and why chronic activation is the problem

When a stressor — physical, psychological, or metabolic — is detected, the hypothalamus releases corticotropin-releasing hormone (CRH), which signals the pituitary to secrete adrenocorticotropic hormone (ACTH), which travels to the adrenal glands and drives cortisol release. In acute situations, this cascade is adaptive: cortisol mobilizes glucose, sharpens focus, suppresses non-essential functions, and prepares the body for the demand. Problems emerge when the stressor is chronic and the HPA axis remains persistently activated — cortisol that should spike and return to baseline instead stays elevated day after day.

For hybrid athletes, the relevant stressors are both training-derived (volume, intensity, frequency, inadequate recovery between sessions) and life-derived (occupational demand, sleep debt, nutritional deficits). Both activate the same HPA axis. The critical variable for hypertrophic adaptation is not any single cortisol spike but the area-under-the-curve of daily cortisol burden across a training week — the chronic baseline that determines whether the hormonal environment favors tissue building or tissue breakdown.

What the 23% reduction means mechanistically

The 23% reduction in morning serum cortisol in the ashwagandha group reflects recalibration of HPA axis set points and negative feedback sensitivity — not acute cortisol blocking. Morning cortisol is the most clinically meaningful measurement point because it captures the trough of the diurnal cycle; reduction there indicates that baseline HPA axis activation (not just acute stress reactivity) has decreased. The withanolides in KSM-66 are believed to enhance glucocorticoid receptor sensitivity in the hypothalamus and pituitary, meaning the system's own negative feedback loop becomes more efficient — less cortisol is needed to signal "enough" and shut down further ACTH release. The practical outcome is lower chronic cortisol, not blunted acute stress response, which preserves the adaptive function of the system while removing the catabolic burden of sustained baseline elevation.

DHEA-S: What the Reduction Actually Means

The 8% reduction in DHEA-S surprised some reviewers of this study because DHEA-S is generally considered a beneficial hormone — higher population-level DHEA-S correlates with better health outcomes, longevity markers, and vitality. Why would reducing it be positive?

The answer is context. DHEA and cortisol are both produced in the adrenal cortex and both rise during HPA axis activation. In chronically stressed individuals, elevated DHEA-S can reflect HPA axis overactivation just as elevated cortisol does — both are markers of sustained adrenal drive. Studies of acute stress, post-traumatic stress disorder, and occupational burnout consistently show DHEA-S elevated alongside cortisol in states of chronic stress. The coordinated 23% cortisol reduction and 8% DHEA-S reduction with ashwagandha indicates the herb is modulating overall HPA axis output — calming an overactive adrenal system — rather than selectively suppressing cortisol while leaving other adrenal products elevated. For healthy individuals with normal baseline DHEA-S, this is an indication of restored balance, not harmful hormone suppression.

Testosterone: What the Data Shows for Male Athletes

The cortisol steal mechanism

Cortisol and testosterone share a common upstream precursor: pregnenolone, derived from cholesterol. Under chronic HPA axis activation, adrenal demand for pregnenolone diverts the shared steroidogenic pathway toward cortisol synthesis at the expense of sex hormone production — a phenomenon variously called the "cortisol steal" or "pregnenolone steal." Simultaneously, elevated cortisol directly suppresses the hypothalamic-pituitary-gonadal (HPG) axis: cortisol inhibits gonadotropin-releasing hormone from the hypothalamus, which reduces luteinizing hormone (LH) from the pituitary, which reduces testosterone synthesis in testicular Leydig cells. The result is the well-documented inverse relationship between chronic cortisol elevation and testosterone levels seen in overtrained athletes, shift workers, and men under sustained occupational stress.

What the 11.4% increase represents

In the men in the ashwagandha group, testosterone rose from 474 ng/dL at baseline to 528 ng/dL at day 60 — an 11.4% increase representing approximately 54 ng/dL. To contextualize the magnitude: testosterone declines approximately 1–2% annually after age 30 in men, translating to roughly 100–150 ng/dL per decade. The 54 ng/dL increase observed after 60 days represents several years' worth of age-related decline reversed — achieved through enhanced endogenous production, not exogenous hormone administration, which preserves normal feedback regulation. The between-group p-value of 0.158 narrowly missed significance with the n=37 male subsample — the within-group change was statistically significant (p = 0.043), and the effect is mechanistically coherent and directionally consistent with the broader literature on ashwagandha and testosterone in men. No testosterone change was observed in women, which is expected given the anatomically different synthesis pathway and much lower baseline concentrations.

Why This Matters for Hybrid Athletes

The hormonal mechanism table

The overtraining hormonal profile

The hormonal signature of overtraining syndrome is well documented: chronically elevated cortisol, suppressed testosterone (in men), disrupted sleep architecture from sustained evening cortisol elevation, impaired glycogen resynthesis (cortisol opposes insulin-mediated glucose uptake), and reduced muscle protein synthesis. Hybrid athletes managing 4–6 training sessions per week across both strength and endurance modalities are at meaningful risk of this profile even without meeting the formal criteria for overtraining syndrome — what is sometimes called "functional overreaching," a state where performance is subtly declining and recovery is incomplete but the athlete has not yet hit the wall. Ashwagandha's HPA axis modulation directly addresses this profile: reducing the cortisol component, partially restoring testosterone via reduced steal, and improving the sleep quality that is both caused by and a cause of cortisol dysregulation. The interaction between concurrent training's AMPK-mTOR interference and cortisol-driven catabolism is covered in the concurrent training interference guide.

The post-session window is the highest-value delivery timing

Cortisol rises substantially during training — particularly during high-intensity endurance work and heavy strength sessions — and remains elevated for 1–3 hours post-session. The 2-hour window after training is when the T:C ratio is most unfavorable and when the anabolic window for muscle protein synthesis is simultaneously open. Delivering KSM-66 in this window — alongside sodium for plasma volume restoration and the inflammatory resolution support of Tart Cherry — addresses the cortisol burden at its peak and creates the hormonal conditions in which the post-workout protein and carbohydrate intake can be maximally leveraged for recovery and adaptation. This is the logic behind Hydrate+'s post-session positioning, not a coincidence of formulation.

Dosing, Timing, and Safety

Dose and form

The study used 240 mg/day of extract standardized to ≥35% withanolide glycosides — delivering 84 mg of active withanolides. The more commonly used clinical dose across the broader literature is 300–600 mg/day of KSM-66 standardized to ≥5% withanolides. At 600 mg with 5% standardization, the active withanolide delivery is 30 mg — lower absolute active compound but within the range producing significant outcomes across multiple trials. The form matters: KSM-66 is root-only, water-extracted, and the most extensively studied standardized extract in human trials. Whole-plant ashwagandha powders or non-standardized products deliver inconsistent withanolide content and should not be considered equivalent.

Timing

The study administered ashwagandha once daily after dinner. Evening timing is mechanistically sensible — cortisol should naturally decline through the evening to facilitate sleep onset, and chronically elevated evening cortisol is one of the most common contributors to difficulty falling asleep in athletes under high training load. For athletes using KSM-66 in a post-session formula like Hydrate+, the post-training window aligns well with this logic when training occurs in the afternoon or evening. Morning training athletes taking Hydrate+ post-session (morning) may benefit from an additional KSM-66-containing supplement in the evening if sleep quality is a specific concern.

Onset timeline

Benefits in this study developed progressively — cortisol reductions were already measurable at day 30 and continued through day 60. This time course reflects adaptogens' mechanism: recalibration of neuroendocrine set points, not acute pharmacological blockade. Athletes starting KSM-66 should plan for 4–8 weeks before evaluating full effectiveness. Subjective indicators worth tracking during this window: sleep onset speed, morning readiness ratings, training motivation, post-session perceived recovery, and — if baseline is known — morning HRV trends.

Safety

The study's perfect safety record (zero adverse events, 100% completion, no hematological abnormalities) aligns with the broader literature and traditional use spanning thousands of years. The most common reported side effect across trials is mild transient GI upset when taken on an empty stomach — resolved by taking with food. Populations requiring caution: pregnant women (uterine stimulant effect in traditional use), individuals on thyroid medication (KSM-66 can modestly increase thyroid hormone levels requiring dose adjustment monitoring), and those on immunosuppressant medications (immunomodulatory effects may interact). Individuals with pre-existing kidney or liver conditions should consult a physician, as with any regular supplement use.

Frequently Asked Questions

What is KSM-66 ashwagandha and how is it different from regular ashwagandha?

KSM-66 is a standardized ashwagandha root extract manufactured by Ixoreal Biomed using a proprietary water-based extraction process that preserves the full-spectrum root chemistry while concentrating withanolide content to ≥5%. It is root-only (not whole-plant including leaf, which contains different alkaloid profiles) and is the form used in the majority of human clinical trials demonstrating cortisol reduction and testosterone support. Non-standardized ashwagandha powders and extracts vary widely in active compound content and cannot be considered equivalent for dosing purposes.

Does ashwagandha blunt the cortisol response to training, or just reduce chronic baseline cortisol?

Based on the mechanism of action — enhanced HPA axis negative feedback sensitivity — ashwagandha primarily reduces chronic baseline cortisol rather than acutely blocking the training-induced cortisol spike. This is the desirable outcome: the acute cortisol response to exercise is adaptive (it mobilizes energy and supports the training stimulus), while chronic baseline elevation is catabolic. Athletes should expect reduced resting and recovery-period cortisol, not blunted performance hormones during hard sessions.

Will ashwagandha increase my testosterone significantly?

The 11% increase in men (474 → 528 ng/dL) is real but modest — it will not transform a clinically low testosterone situation into normal range. For men with training-suppressed testosterone or age-related decline in the context of high concurrent training loads, the effect is meaningful. For men with already-normal testosterone, the benefit is primarily in maintaining the favorable T:C ratio during periods of high training volume. Women do not see testosterone changes from KSM-66 at these doses.

How long until I notice effects from KSM-66?

The study showed progressive benefits over 60 days, with measurable changes appearing by day 30. Subjectively, most users report improved sleep quality and post-session recovery sense within 2–4 weeks. Full cortisol recalibration develops over 6–8 weeks of consistent daily use. This is not an acute-effect supplement — it works through sustained neuroendocrine recalibration, not pharmacological blockade, and requires consistent daily intake to maintain benefit.

Is it safe to take KSM-66 year-round?

The evidence supports long-term daily use for healthy adults. The study population showed no adverse hematological, hepatic, or renal markers over 60 days, and the traditional Ayurvedic use of ashwagandha as a daily tonic spans thousands of years without documented toxicity at typical doses. Cycling is not required — there is no evidence of tolerance development or diminishing returns with continuous use. Athletes with autoimmune conditions, thyroid disease, or who are taking medications affecting hormone systems should discuss ongoing use with a knowledgeable clinician.

Does ashwagandha interact with creatine or pre-workout supplements?

No clinically significant interactions are documented between ashwagandha and either creatine monohydrate or the ingredients in a standard pre-workout (caffeine, citrulline, beta-alanine, tyrosine). The three products address different physiological variables — cortisol and hormonal environment (KSM-66), PCr pool and anabolic signaling (creatine), and session quality and perceived effort (pre-workout) — and are designed to work together as a complete stack for hybrid athletes.

Conclusion

The research on KSM-66 ashwagandha is among the most directly applicable in the adaptogen literature for hybrid athletes. The HPA axis modulation mechanism — enhanced negative feedback sensitivity reducing chronic baseline cortisol — addresses a physiological problem that is endemic to high-volume concurrent training and poorly managed by standard recovery protocols. The 23% cortisol reduction, 8% DHEA-S normalization, and 11% testosterone increase in men documented in a 60-day RCT represent meaningful shifts in the hormonal environment that determines whether accumulated training stress converts to adaptation or accumulates as catabolic damage.

For athletes who train hard and recover deliberately, KSM-66 at 600 mg taken post-session is the most evidence-supported single intervention for managing the cortisol burden that high-frequency concurrent training creates. Paired with creatine for PCr availability and anabolic signaling, and a clinical pre-workout for session quality, it forms the hormonal management layer of a complete hybrid athlete supplement stack. For further reading: concurrent training interference guide · recovery demands in hybrid training · creatine and muscle growth guide · building muscle as an endurance athlete · hybrid athlete supplement stack guide